Minerva Neurosciences, Inc. (NERV) Stock

About Minerva Neurosciences, Inc.

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

Minerva Neurosciences, Inc. is led by CEO Remy Luthringer, employs 8 people, headquartered in US, publicly traded since 2014.

Minerva Neurosciences, Inc. (NERV) stock trades at $4.14 with a market capitalization of $28.92M. The stock is valued at a price-to-earnings (P/E) ratio of -0.14, price-to-book of -0.70, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.76 and $12.46, and currently trades 66.8% below its 52-week high.

On profitability, Minerva Neurosciences, Inc. generates a return on equity (ROE) of 359.80% — well above the market average, a sign of a high-quality business, return on capital employed of -31.13%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.minervaneurosciences.com